Elevated BUBR1 expression is associated with poor survival in early breast cancer patients: 15-year follow-up analysis.

BUBR1 (budding uninhibited by benzimidazole-related 1) represents the component of a controlling complex in mitosis. Defects in mitotic control complex result in chromosomal instability and, as a result, disturb the mitotic process. This study was aimed at examining the prognostic value linked to the expression of BUBR1 in a group of patients with breast cancer. We analyzed the expression of BUBR1 in 98 stage II breast cancer patients with a median follow-up of 15 years. Immunohistochemical reactions were performed using monoclonal antibodies against BUBR1. We also studied the prognostic value of BUBR1 mRNA expression using the Kaplan-Meier (KM) plotter, which assessed the effect of 22,277 genes on survival in 2422 breast cancer patients. A background database was established using gene expression data and survival information on 2422 patients downloaded from the Gene Expression Omnibus (GEO; Affymetrix HGU133A and HGU133+2 microarrays). The median relapse-free survival was 6.43 years. Univariate and multivariate analyses showed that higher expression of BUBR1 was typical for cases of shorter overall survival, disease-free time, and disease-specific survival. KM plotter analysis showed that elevated BUBR1 mRNA expression had a negative impact on patients' relapse-free, distant metastases-free, and overall survival. Elevated BUBR1 expression was associated with poor survival in early stage breast cancer patients.

Citation

Adam Maciejczyk, Jolanta Szelachowska, Bogdan Czapiga, Rafał Matkowski, Agnieszka Hałoń, Balázs Györffy, Paweł Surowiak. Elevated BUBR1 expression is associated with poor survival in early breast cancer patients: 15-year follow-up analysis. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. 2013 May;61(5):330-9

Mesh Tags

Substances

PMID: 23392733

search → result